LianBio Uncategorized Contracts & Agreements
11 Contracts & Agreements
- Description of Securities (Filed With SEC on March 28, 2023)
- Second Amendment (Filed With SEC on March 31, 2022)
- Description of (Filed With SEC on March 31, 2022)
- Option Agreement, dated October 18, 2021, by and among LianBio, LianBio Ophthalmology and Tarsus Pharmaceuticals, Inc (Filed With SEC on October 20, 2021)
- Specimen Certificate evidencing the Ordinary Shares (Filed With SEC on October 20, 2021)
- Director Nomination Agreement, dated October 8, 2021, by and among LianBio and Perceptive Life Sciences Master Fund, Ltd., LEV LB Holdings, LP, Perceptive Xontogency Venture Fund,... (Filed With SEC on October 8, 2021)
- Novation Agreement, dated October 11, 2020, by and among LianBio, LianBio Licensing LLC and QED Therapeutics, Inc (Filed With SEC on October 1, 2021)
- Exclusivity Agreement, dated October 16, 2019, by and between LianBio and BridgeBio Pharma LLC (Filed With SEC on October 1, 2021)
- Equity Holders Agreement, dated August 10, 2020, by and among LianBio, Lian Cardiovascular and MyoKardia, Inc (Filed With SEC on October 1, 2021)
- Amended and Restated Option Agreement, dated as of August 10, 2020, by and among LianBio and MyoKardia, Inc. and QED Therapeutics, Inc (Filed With SEC on October 1, 2021)
- Information Rights Letter of BridgeBio Pharma LLC, dated October 16, 2019, by and between the Company and BridgeBio Pharma LLC (Filed With SEC on October 1, 2021)
